INCY - Incyte Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
116.60
+2.29 (+2.00%)
At close: 4:00PM EDT

116.90 +0.30 (0.26%)
Pre-Market: 8:03AM EDT

Stock chart is not supported by your current browser
Previous Close114.31
Open114.89
Bid116.90 x 300
Ask123.30 x 100
Day's Range114.31 - 116.67
52 Week Range83.01 - 153.15
Volume1,821,407
Avg. Volume1,501,655
Market Cap24.56B
Beta1.48
PE Ratio (TTM)-147.22
EPS (TTM)-0.79
Earnings DateOct 31, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est148.61
Trade prices are not sourced from all markets
  • Incyte Might Win a Cancer-Drug Battle But Lose the War
    Bloomberg17 hours ago

    Incyte Might Win a Cancer-Drug Battle But Lose the War

    Even if its suit over alleged IP theft succeeds, the competition is already fierce.

  • Capital Cube23 hours ago

    ETFs with exposure to Incyte Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Dailyyesterday

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease
    Investor's Business Dailyyesterday

    Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease

    Incyte stands out among biotech companies chasing next-generation treatments that work with patients' own immune systems to combat cancer.

  • Business Wire5 days ago

    Incyte to Report Third Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017.

  • Forbes7 days ago

    One Of Biotech's Hottest Names Embraces Pharma's Bygone Era

    Incyte has one cancer blockbuster, and it's got Wall Street banking on another. Its secret: embracing an older age of pharma.

  • American City Business Journals11 days ago

    Take a look: Incyte unveils new global headquarters in Wilmington

    While one may expect to have to go to a local park to find a walking trail, community gardens, putting green and a pickleball court side by side, employees of Incyte Corp. will find all those outdoor amenities at the biopharmaceutical company's new global headquarters in Wilmington. Incyte CEO Herve Hoppenot said the expansion was needed to provide more space for the company's growing research and development activities.

  • Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware
    Business Wire11 days ago

    Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware

    Incyte Corporation and Cancer Support Community Delaware today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for cancer patients, their caregivers and family members living in Delaware.

  • Capital Cube12 days ago

    ETFs with exposure to Incyte Corp. : October 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Forbes13 days ago

    Cancer-Cure Makers Make Great Takeover Stocks

    This company's impressive technology portfolio make it a great acquisition candidate.

  • 3 Stocks That Turned $7,000 Into $130,200
    Motley Fool19 days ago

    3 Stocks That Turned $7,000 Into $130,200

    There have been some big winners over the past decade, but few have surpassed Priceline Group, Regeneron Pharmaceuticals, and Incyte.

  • Agenus (AGEN) Remains Focused on Drug Development Programs
    Zacks19 days ago

    Agenus (AGEN) Remains Focused on Drug Development Programs

    Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $8.79 billion.

  • Investopedia22 days ago

    12 Stocks That Will Push the S&P 500 Higher

    Goldman Sachs says sales growth will be the key ingredient driving stocks higher

  • Capital Cube22 days ago

    ETFs with exposure to Incyte Corp. : September 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
    Zacks22 days ago

    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

  • 3 Monster Biotech Stocks in the Making
    Motley Fool23 days ago

    3 Monster Biotech Stocks in the Making

    They've got successful drugs. They're profitable. All these biotechs need to become huge is a little luck and time.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit26 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • 3 Small-Cap Biotech Stocks to Buy This Fall
    Motley Fool26 days ago

    3 Small-Cap Biotech Stocks to Buy This Fall

    Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.

  • GlobeNewswire28 days ago

    Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

    UTRECHT, The Netherlands, Sept. 19, 2017-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second ...

  • GlobeNewswire29 days ago

    Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell

    What: Incyte Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, will visit the Nasdaq MarketSite in Times Square. In honor ...

  • Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
    Zackslast month

    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

  • Reuterslast month

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.

  • Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?
    Simply Wall St.last month

    Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?

    Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock See our latest analysis for INCY What is INCY worth? INCY appears to beRead More...

  • Reuterslast month

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.